Introduction to TESAMORELIN therapy
Tesamorelin is a medication that can help increase the natural production of Human Growth Hormone (HGH) in the body. It is an injectable peptide that binds to and stimulates the same receptors in the body as our own natural Growth Hormone-Releasing Hormone (GHRH). Tesamorelin has been clinically proven to raise both growth hormone and IGF-1 levels, while not significantly affecting other hormones in the body. It is currently the most effective GH releasing hormone available.
Benefits of Tesamorelin therapy:
Tesamorelin has been proven to have a variety of positive effects on the human body, including reducing carotid intima-media thickness (cIMT), visceral adipose tissue (VAT), and c-reactive protein (CRP). Additionally, this particular human growth hormone secretagogue has been associated with increased natural production of HGH (human growth hormone) and IGF-1 (Insulin Growth Factor – 1), as well as decreased triglycerides, without any alteration to glucose parameters. Furthermore, Tesamorelin has been observed to improve cognitive function in elderly adults or those at risk for Alzheimer’s disease due to mild cognitive impairment.
Clinical trials have demonstrated that Tesamorelin is more effective in reducing abdominal fat than human growth hormone, with fewer side effects. This was observed in both HIV-positive and non-HIV-positive individuals. In one study, 10.9% of HIV-positive patients experienced a significant reduction in their deep belly fat, as well as a decrease in trunk fat, waist size, and waist-to-hip ratio. However, there was no change in limb and abdominal subcutaneous fat levels. Additionally, Tesamorelin caused an increase in insulin-like growth factor 1, but no alteration in glucose parameters was observed. Most patients did not experience any negative side effects. However, the positive effects were only temporary, as those who switched to a placebo lost their improvements. After six months, the patients had an eighteen percent reduction in visceral fat levels.
The objective of this study was to analyze the effects that the novel GHTH analog, tesamorelin, has on endogenous GH pulsatility and insulin sensitivity in healthy males. 13 males aged 45-47, with a body mass index of 27.3 to 1.2kg, were administered tesamorelin 2mg on a daily basis for two weeks. After two weeks, assessments were made and it was found that tesamorelin had augmented basal and pulsatile GH secretion. In addition, IGF-1 was significantly increased, although peripheral insulin-stimulated glucose remained unchanged.
Clinical trials of tesamorelin have demonstrated that it is able to reduce abdominal fat with fewer side effects than human growth hormone alone. However, the effects of tesamorelin can be reversed when it is discontinued, depending on the preference of the individual taking it. The drug has also been seen to reduce lipodystrophy in HIV-infected individuals as well as abdominal fat in non-HIV infected individuals.
What Are The Side Effects Of Tesamorelin?
You may experience some side effects while taking Tesamorelin, including allergic reactions such as skin rashes, itching, hives, and swelling of the face, tongue, or lips. Other side effects may include chest pain or tightness, increased hunger or thirst, increased urination, feeling weak and tired, and palpitations. There are also less serious side effects which do not require medical attention, such as a depressed mood, muscle pain, nausea, vomiting, pain, redness or irritation at the injection site, tingling or numbness of the hands and feet, and swelling of the ankles, feet, or hands. If these side effects are bothersome, make sure to inform your healthcare provider.
What Is The Right Way To Use Tesamorelin?
The correct way to administer Tesamorelin is by injection under the skin. You may be taught how to self-inject the medication, however, it is important to follow the exact instructions provided by your healthcare provider and take this medication at the prescribed frequency. Do not take the medication more often than prescribed.
It is essential to properly dispose of used needles and syringes by placing them in a sharps container. If you do not have a sharp container, contact your healthcare provider to acquire one.
Do not use the medication if it contains solid particles, is cloudy or colored. The medication should be clear and colorless.
You will be given a patient package insert with the product which includes a prescription and refills. It is important to read this information carefully before administering the medicine.
Tesamorelin vs Ipomaralin
Research conducted on tesamorelin and ipamorelin has shown that both peptides can increase the secretion and production of human growth hormone (HGH) in laboratory and animal studies. Tesamorelin has been approved by the FDA and undergone human clinical trials, and ipamorelin has not yet done so. Additionally, ipamorelin has been found to not have any adverse effects on ACTH and cortisol levels, based on the rat and swine studies.
Researchers in the growth hormone therapy field are interested in the similarities and differences between tesamorelin and ipamorelin. Both peptides are known to stimulate the production and release of HGH. However, the two have different potential benefits and side effects.
Tesamorelin is FDA approved for reducing abdominal fat in HIV-infected patients with lipodystrophy, while ipamorelin has yet to complete human clinical trials and is usually administered in conjunction with a GHRH such as tesamorelin or CJC-1295.
Tesamorelin is a powerful growth hormone releasing peptide developed by Novo Nordisk, which is approved by the FDA for the treatment of Visceral Body Fat (VAT). It is the quickest peptide to produce an increase in IGF-1, and it also stimulates growth hormone secretion and the production of IGF-1 in the liver without affecting ACTH or Cortisol production.
This combination of two peptides Tesamorelin and Ipamorelin is an effective and cost-efficient way to quickly and safely maximize hormone production, providing all the associated benefits.